Arbutus Biopharma
Arbutus Biopharma
Arbutus Biopharma (pronunciation: /ɑːrˈbjuːtəs baɪoʊˈfɑːrmə/) is a biopharmaceutical company that focuses on discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (HBV).
Etymology
The name "Arbutus" is derived from the Latin Arbutus unedo, a species of tree known for its resilience and longevity, symbolizing the company's commitment to developing a cure for chronic hepatitis B. "Biopharma" is a portmanteau of "biological" and "pharmaceutical", indicating the company's focus on drug development using biological systems.
History
Arbutus Biopharma was founded in 2007 as Tekmira Pharmaceuticals. In 2015, Tekmira merged with OnCore Biopharma to form Arbutus Biopharma, with a renewed focus on developing a cure for chronic hepatitis B.
Research and Development
Arbutus Biopharma's research and development efforts are primarily focused on the discovery and development of drugs that can inhibit the replication of the hepatitis B virus and provide a cure for chronic hepatitis B infection. The company's pipeline includes a range of drug candidates, including RNA interference (RNAi) therapeutics, capsid inhibitors, and immune modulators.
Related Terms
- Biopharmaceutical
- Chronic hepatitis B
- Liver
- Hepatitis B virus
- RNA interference
- Capsid
- Immune modulator
External links
- Medical encyclopedia article on Arbutus Biopharma
- Wikipedia's article - Arbutus Biopharma
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski